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Dr. Fu has published over 240 peer-reviewed research and review papers, including 6 papers published in Cancer Research. The research in Dr. Fu\'s laboratory has been supported by several grants (National Natural Science Foundation of China/863 Project/973 Project). In addition to his research, Dr. Fu has been actively involved in teaching courses in cancer drug pharmacology and toxicology, and guiding graduate and doctorial students and postdoctors in research and career development. Dr. Fu vividly provides extensive services to the scientific community which includes various committees and advisory panels/boards. He is chairman of Board of directors, Anticancer Drug Section, Guangdong Anticancer Society and an editorial member of scientific journals (*e.g., Molecular Pharmacology*, *American Journal of Cancer Research*, *Recent Patents on Anti-Cancer Drug Discovery*, *Acta Pharmaceutica Sinica B*, *etc.*). He has also served as a reviewer for national research grants of Italy, Czech Republic, and China and has been invited to present his works in many international and national meetings.

Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
